Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Hepatocellular 17Stomach Neoplasms 8Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Rectal Neoplasms 5Neoplasm Metastasis 4Triple Negative Breast Neoplasms 3Pancreatic Neoplasms 3Nasopharyngeal Carcinoma 3Esophageal Neoplasms 3Uterine Cervical Neoplasms 2Solid Tumor 2Recurrence 2Lung Neoplasms 2Esophageal Squamous Cell Carcinoma 2Endometrial Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Spinocerebellar Degenerations 1Small Cell Lung Carcinoma 1Resectable NSCLC 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasms, Unknown Primary 1Neoplasms 1Metastatic Gastroesophageal Junction Adenocarcinoma 1Meningeal Carcinomatosis 1MSI-H 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Injections 20Carboplatin 9pembrolizumab 8Bevacizumab 6Pemetrexed 5Paclitaxel 5Leucovorin 5Fluorouracil 5fludarabine 4Oxaliplatin 4Docetaxel 4sotorasib 3atezolizumab 3Drug Therapy 3Cyclophosphamide 3Capecitabine 3trifluridine tipiracil drug combination 2trametinib 2toripalimab 2spartalizumab 2palbociclib 2olaparib 2Panitumumab 2Immune Checkpoint Inhibitors 2Fulvestrant 2Etoposide 2Cisplatin 2Cetuximab 2130-nm albumin-bound paclitaxel 2zimberelimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Solid Tumors × sintilimab × 1 year × Clear all
NCT05718219 2025-08-13

Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0348 in Advanced Solid Tumors

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 1 Active not recruiting
408 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡